nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefenamic acid—PTGS2—Lenalidomide—hematologic cancer	0.0689	0.118	CbGbCtD
Mefenamic acid—AKR1C3—Doxorubicin—hematologic cancer	0.0651	0.112	CbGbCtD
Mefenamic acid—PTGS2—Thalidomide—hematologic cancer	0.0368	0.0632	CbGbCtD
Mefenamic acid—PTGS1—Bortezomib—hematologic cancer	0.0357	0.0613	CbGbCtD
Mefenamic acid—PTGS1—Thalidomide—hematologic cancer	0.0311	0.0534	CbGbCtD
Mefenamic acid—PTGS1—Ifosfamide—hematologic cancer	0.0274	0.047	CbGbCtD
Mefenamic acid—PTGS1—Imatinib—hematologic cancer	0.0261	0.0449	CbGbCtD
Mefenamic acid—PTGS2—Triamcinolone—hematologic cancer	0.0255	0.0438	CbGbCtD
Mefenamic acid—CYP2C9—Bexarotene—hematologic cancer	0.0234	0.0403	CbGbCtD
Mefenamic acid—PTGS2—Betamethasone—hematologic cancer	0.0219	0.0376	CbGbCtD
Mefenamic acid—CYP2C8—Bortezomib—hematologic cancer	0.0206	0.0354	CbGbCtD
Mefenamic acid—CYP2C9—Idarubicin—hematologic cancer	0.0194	0.0334	CbGbCtD
Mefenamic acid—CYP2C8—Ifosfamide—hematologic cancer	0.0158	0.0271	CbGbCtD
Mefenamic acid—PTGS2—Cisplatin—hematologic cancer	0.0158	0.0271	CbGbCtD
Mefenamic acid—PTGS2—Etoposide—hematologic cancer	0.0155	0.0266	CbGbCtD
Mefenamic acid—CYP2C9—Bortezomib—hematologic cancer	0.0144	0.0247	CbGbCtD
Mefenamic acid—CYP2C8—Nilotinib—hematologic cancer	0.0137	0.0236	CbGbCtD
Mefenamic acid—PTGS1—Etoposide—hematologic cancer	0.0131	0.0225	CbGbCtD
Mefenamic acid—PTGS2—Dexamethasone—hematologic cancer	0.0127	0.0219	CbGbCtD
Mefenamic acid—CYP2C9—Thalidomide—hematologic cancer	0.0125	0.0215	CbGbCtD
Mefenamic acid—CYP2C9—Teniposide—hematologic cancer	0.0119	0.0205	CbGbCtD
Mefenamic acid—CYP2C9—Ifosfamide—hematologic cancer	0.011	0.0189	CbGbCtD
Mefenamic acid—CYP2C9—Imatinib—hematologic cancer	0.0105	0.0181	CbGbCtD
Mefenamic acid—CYP2C9—Nilotinib—hematologic cancer	0.00956	0.0164	CbGbCtD
Mefenamic acid—CYP2C8—Etoposide—hematologic cancer	0.00755	0.013	CbGbCtD
Mefenamic acid—PTGS2—ovarian follicle—hematologic cancer	0.00671	0.224	CbGeAlD
Mefenamic acid—CYP2C8—Dexamethasone—hematologic cancer	0.00621	0.0107	CbGbCtD
Mefenamic acid—CYP2C9—Cisplatin—hematologic cancer	0.00536	0.0092	CbGbCtD
Mefenamic acid—CYP2C9—Dexamethasone—hematologic cancer	0.00433	0.00744	CbGbCtD
Mefenamic acid—AKR1C2—testis—hematologic cancer	0.00421	0.14	CbGeAlD
Mefenamic acid—AKR1C2—lymph node—hematologic cancer	0.00305	0.102	CbGeAlD
Mefenamic acid—AKR1C3—blood—hematologic cancer	0.00159	0.053	CbGeAlD
Mefenamic acid—AKR1C3—bone marrow—hematologic cancer	0.00154	0.0513	CbGeAlD
Mefenamic acid—AKR1C3—lung—hematologic cancer	0.00139	0.0464	CbGeAlD
Mefenamic acid—AKR1C3—testis—hematologic cancer	0.00131	0.0438	CbGeAlD
Mefenamic acid—Acetylsalicylic acid—HSPA5—hematologic cancer	0.00123	0.251	CrCbGaD
Mefenamic acid—Acetylsalicylic acid—NFKBIA—hematologic cancer	0.00114	0.233	CrCbGaD
Mefenamic acid—AKR1C3—Podofilox—Teniposide—hematologic cancer	0.00105	0.235	CbGdCrCtD
Mefenamic acid—CYP2C8—hematopoietic system—hematologic cancer	0.00105	0.0349	CbGeAlD
Mefenamic acid—AKR1C3—lymph node—hematologic cancer	0.000952	0.0318	CbGeAlD
Mefenamic acid—CYP2C9—hematopoietic system—hematologic cancer	0.000929	0.031	CbGeAlD
Mefenamic acid—PTGS1—hematopoietic system—hematologic cancer	0.000848	0.0283	CbGeAlD
Mefenamic acid—PTGS2—hematopoietic system—hematologic cancer	0.00081	0.027	CbGeAlD
Mefenamic acid—CYP2C8—blood—hematologic cancer	0.000693	0.0231	CbGeAlD
Mefenamic acid—AKR1C3—Vincristine—Vinorelbine—hematologic cancer	0.000668	0.15	CbGdCrCtD
Mefenamic acid—AKR1C3—Podofilox—Etoposide—hematologic cancer	0.000624	0.14	CbGdCrCtD
Mefenamic acid—CYP2C9—blood—hematologic cancer	0.000615	0.0205	CbGeAlD
Mefenamic acid—CYP2C8—testis—hematologic cancer	0.000573	0.0191	CbGeAlD
Mefenamic acid—PTGS1—blood—hematologic cancer	0.000562	0.0187	CbGeAlD
Mefenamic acid—Meclofenamic acid—ALOX5—hematologic cancer	0.000539	0.11	CrCbGaD
Mefenamic acid—AKR1C3—Vinblastine—Vinorelbine—hematologic cancer	0.000537	0.12	CbGdCrCtD
Mefenamic acid—PTGS2—blood—hematologic cancer	0.000537	0.0179	CbGeAlD
Mefenamic acid—AKR1C3—Vincristine—Vinblastine—hematologic cancer	0.000534	0.12	CbGdCrCtD
Mefenamic acid—PTGS2—bone marrow—hematologic cancer	0.000519	0.0173	CbGeAlD
Mefenamic acid—Acetylsalicylic acid—TP53—hematologic cancer	0.000505	0.103	CrCbGaD
Mefenamic acid—PTGS1—lung—hematologic cancer	0.000492	0.0164	CbGeAlD
Mefenamic acid—PTGS2—lung—hematologic cancer	0.000471	0.0157	CbGeAlD
Mefenamic acid—PTGS1—testis—hematologic cancer	0.000465	0.0155	CbGeAlD
Mefenamic acid—AKR1C3—Vinblastine—Vincristine—hematologic cancer	0.00043	0.0962	CbGdCrCtD
Mefenamic acid—PTGS1—lymph node—hematologic cancer	0.000337	0.0112	CbGeAlD
Mefenamic acid—PTGS2—lymph node—hematologic cancer	0.000322	0.0107	CbGeAlD
Mefenamic acid—Diclofenac—ALOX5—hematologic cancer	0.000301	0.0616	CrCbGaD
Mefenamic acid—Diclofenac—UGT1A1—hematologic cancer	0.000265	0.0541	CrCbGaD
Mefenamic acid—Flurbiprofen—UGT1A1—hematologic cancer	0.000259	0.0529	CrCbGaD
Mefenamic acid—PTGS2—Fluocinonide—Dexamethasone—hematologic cancer	0.00013	0.0291	CbGdCrCtD
Mefenamic acid—PTGS2—Fluocinonide—Betamethasone—hematologic cancer	0.00013	0.0291	CbGdCrCtD
Mefenamic acid—PTGS2—Fluocinonide—Triamcinolone—hematologic cancer	0.000127	0.0285	CbGdCrCtD
Mefenamic acid—Fenoprofen—ALB—hematologic cancer	9.73e-05	0.0199	CrCbGaD
Mefenamic acid—Acetylsalicylic acid—ALB—hematologic cancer	8.8e-05	0.018	CrCbGaD
Mefenamic acid—Acetylsalicylic acid—ABCB1—hematologic cancer	8.4e-05	0.0172	CrCbGaD
Mefenamic acid—PTGS2—Fluticasone Propionate—Dexamethasone—hematologic cancer	7.85e-05	0.0176	CbGdCrCtD
Mefenamic acid—PTGS2—Fluticasone Propionate—Betamethasone—hematologic cancer	7.85e-05	0.0176	CbGdCrCtD
Mefenamic acid—PTGS2—Fluticasone Propionate—Triamcinolone—hematologic cancer	7.67e-05	0.0172	CbGdCrCtD
Mefenamic acid—Salicylic acid—ALB—hematologic cancer	7.24e-05	0.0148	CrCbGaD
Mefenamic acid—Salicylic acid—ABCB1—hematologic cancer	6.91e-05	0.0141	CrCbGaD
Mefenamic acid—Diclofenac—ALB—hematologic cancer	6.49e-05	0.0133	CrCbGaD
Mefenamic acid—Flurbiprofen—ALB—hematologic cancer	6.35e-05	0.013	CrCbGaD
Mefenamic acid—Diclofenac—ABCB1—hematologic cancer	6.19e-05	0.0126	CrCbGaD
Mefenamic acid—Ketoprofen—ALB—hematologic cancer	5.75e-05	0.0117	CrCbGaD
Mefenamic acid—Paraesthesia—Dexamethasone—hematologic cancer	3.03e-05	0.00011	CcSEcCtD
Mefenamic acid—Paraesthesia—Betamethasone—hematologic cancer	3.03e-05	0.00011	CcSEcCtD
Mefenamic acid—Discomfort—Prednisone—hematologic cancer	3.03e-05	0.00011	CcSEcCtD
Mefenamic acid—Mental disorder—Methotrexate—hematologic cancer	3.03e-05	0.00011	CcSEcCtD
Mefenamic acid—Rash—Gemcitabine—hematologic cancer	3.03e-05	0.00011	CcSEcCtD
Mefenamic acid—Dermatitis—Gemcitabine—hematologic cancer	3.03e-05	0.000109	CcSEcCtD
Mefenamic acid—Tinnitus—Epirubicin—hematologic cancer	3.02e-05	0.000109	CcSEcCtD
Mefenamic acid—Haemoglobin—Doxorubicin—hematologic cancer	3.01e-05	0.000109	CcSEcCtD
Mefenamic acid—Headache—Gemcitabine—hematologic cancer	3.01e-05	0.000109	CcSEcCtD
Mefenamic acid—Nausea—Vincristine—hematologic cancer	3.01e-05	0.000109	CcSEcCtD
Mefenamic acid—Haemorrhage—Doxorubicin—hematologic cancer	3e-05	0.000108	CcSEcCtD
Mefenamic acid—Hepatitis—Doxorubicin—hematologic cancer	3e-05	0.000108	CcSEcCtD
Mefenamic acid—Dyspepsia—Dexamethasone—hematologic cancer	2.97e-05	0.000107	CcSEcCtD
Mefenamic acid—Dyspepsia—Betamethasone—hematologic cancer	2.97e-05	0.000107	CcSEcCtD
Mefenamic acid—Urinary tract disorder—Doxorubicin—hematologic cancer	2.96e-05	0.000107	CcSEcCtD
Mefenamic acid—Urticaria—Triamcinolone—hematologic cancer	2.96e-05	0.000107	CcSEcCtD
Mefenamic acid—Asthenia—Etoposide—hematologic cancer	2.95e-05	0.000106	CcSEcCtD
Mefenamic acid—Body temperature increased—Triamcinolone—hematologic cancer	2.94e-05	0.000106	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Prednisone—hematologic cancer	2.94e-05	0.000106	CcSEcCtD
Mefenamic acid—Oedema—Prednisone—hematologic cancer	2.94e-05	0.000106	CcSEcCtD
Mefenamic acid—Urethral disorder—Doxorubicin—hematologic cancer	2.94e-05	0.000106	CcSEcCtD
Mefenamic acid—Decreased appetite—Betamethasone—hematologic cancer	2.94e-05	0.000106	CcSEcCtD
Mefenamic acid—Decreased appetite—Dexamethasone—hematologic cancer	2.94e-05	0.000106	CcSEcCtD
Mefenamic acid—Nausea—Mitoxantrone—hematologic cancer	2.93e-05	0.000106	CcSEcCtD
Mefenamic acid—Nausea—Irinotecan—hematologic cancer	2.93e-05	0.000106	CcSEcCtD
Mefenamic acid—Infection—Prednisone—hematologic cancer	2.92e-05	0.000106	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Betamethasone—hematologic cancer	2.92e-05	0.000105	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Dexamethasone—hematologic cancer	2.92e-05	0.000105	CcSEcCtD
Mefenamic acid—Pruritus—Etoposide—hematologic cancer	2.9e-05	0.000105	CcSEcCtD
Mefenamic acid—Shock—Prednisone—hematologic cancer	2.89e-05	0.000105	CcSEcCtD
Mefenamic acid—Arrhythmia—Epirubicin—hematologic cancer	2.89e-05	0.000105	CcSEcCtD
Mefenamic acid—Tachycardia—Prednisone—hematologic cancer	2.87e-05	0.000104	CcSEcCtD
Mefenamic acid—Alopecia—Epirubicin—hematologic cancer	2.86e-05	0.000103	CcSEcCtD
Mefenamic acid—Skin disorder—Prednisone—hematologic cancer	2.86e-05	0.000103	CcSEcCtD
Mefenamic acid—Nausea—Gemcitabine—hematologic cancer	2.86e-05	0.000103	CcSEcCtD
Mefenamic acid—Vomiting—Cisplatin—hematologic cancer	2.85e-05	0.000103	CcSEcCtD
Mefenamic acid—Vision blurred—Methotrexate—hematologic cancer	2.84e-05	0.000103	CcSEcCtD
Mefenamic acid—Mental disorder—Epirubicin—hematologic cancer	2.84e-05	0.000103	CcSEcCtD
Mefenamic acid—Erythema multiforme—Doxorubicin—hematologic cancer	2.83e-05	0.000102	CcSEcCtD
Mefenamic acid—Rash—Cisplatin—hematologic cancer	2.83e-05	0.000102	CcSEcCtD
Mefenamic acid—Dermatitis—Cisplatin—hematologic cancer	2.82e-05	0.000102	CcSEcCtD
Mefenamic acid—Diarrhoea—Etoposide—hematologic cancer	2.81e-05	0.000102	CcSEcCtD
Mefenamic acid—Anorexia—Prednisone—hematologic cancer	2.8e-05	0.000101	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Methotrexate—hematologic cancer	2.8e-05	0.000101	CcSEcCtD
Mefenamic acid—Tinnitus—Doxorubicin—hematologic cancer	2.79e-05	0.000101	CcSEcCtD
Mefenamic acid—Anaemia—Methotrexate—hematologic cancer	2.78e-05	0.000101	CcSEcCtD
Mefenamic acid—Feeling abnormal—Dexamethasone—hematologic cancer	2.78e-05	0.000101	CcSEcCtD
Mefenamic acid—Feeling abnormal—Betamethasone—hematologic cancer	2.78e-05	0.000101	CcSEcCtD
Mefenamic acid—Flatulence—Epirubicin—hematologic cancer	2.78e-05	0.0001	CcSEcCtD
Mefenamic acid—Tension—Epirubicin—hematologic cancer	2.77e-05	0.0001	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Betamethasone—hematologic cancer	2.76e-05	9.98e-05	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.76e-05	9.98e-05	CcSEcCtD
Mefenamic acid—Nervousness—Epirubicin—hematologic cancer	2.74e-05	9.9e-05	CcSEcCtD
Mefenamic acid—Malaise—Methotrexate—hematologic cancer	2.72e-05	9.82e-05	CcSEcCtD
Mefenamic acid—Dizziness—Etoposide—hematologic cancer	2.71e-05	9.81e-05	CcSEcCtD
Mefenamic acid—Vertigo—Methotrexate—hematologic cancer	2.71e-05	9.78e-05	CcSEcCtD
Mefenamic acid—Leukopenia—Methotrexate—hematologic cancer	2.7e-05	9.75e-05	CcSEcCtD
Mefenamic acid—Urticaria—Betamethasone—hematologic cancer	2.68e-05	9.7e-05	CcSEcCtD
Mefenamic acid—Urticaria—Dexamethasone—hematologic cancer	2.68e-05	9.7e-05	CcSEcCtD
Mefenamic acid—Dizziness—Prednisolone—hematologic cancer	2.68e-05	9.68e-05	CcSEcCtD
Mefenamic acid—Arrhythmia—Doxorubicin—hematologic cancer	2.68e-05	9.68e-05	CcSEcCtD
Mefenamic acid—Asthenia—Triamcinolone—hematologic cancer	2.67e-05	9.65e-05	CcSEcCtD
Mefenamic acid—Body temperature increased—Betamethasone—hematologic cancer	2.67e-05	9.65e-05	CcSEcCtD
Mefenamic acid—Abdominal pain—Betamethasone—hematologic cancer	2.67e-05	9.65e-05	CcSEcCtD
Mefenamic acid—Abdominal pain—Dexamethasone—hematologic cancer	2.67e-05	9.65e-05	CcSEcCtD
Mefenamic acid—Body temperature increased—Dexamethasone—hematologic cancer	2.67e-05	9.65e-05	CcSEcCtD
Mefenamic acid—Nausea—Cisplatin—hematologic cancer	2.66e-05	9.62e-05	CcSEcCtD
Mefenamic acid—Insomnia—Prednisone—hematologic cancer	2.66e-05	9.62e-05	CcSEcCtD
Mefenamic acid—Vision blurred—Epirubicin—hematologic cancer	2.66e-05	9.6e-05	CcSEcCtD
Mefenamic acid—Alopecia—Doxorubicin—hematologic cancer	2.65e-05	9.57e-05	CcSEcCtD
Mefenamic acid—Paraesthesia—Prednisone—hematologic cancer	2.64e-05	9.55e-05	CcSEcCtD
Mefenamic acid—Pruritus—Triamcinolone—hematologic cancer	2.63e-05	9.52e-05	CcSEcCtD
Mefenamic acid—Mental disorder—Doxorubicin—hematologic cancer	2.63e-05	9.49e-05	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Epirubicin—hematologic cancer	2.62e-05	9.45e-05	CcSEcCtD
Mefenamic acid—Convulsion—Methotrexate—hematologic cancer	2.61e-05	9.43e-05	CcSEcCtD
Mefenamic acid—Vomiting—Etoposide—hematologic cancer	2.61e-05	9.43e-05	CcSEcCtD
Mefenamic acid—Anaemia—Epirubicin—hematologic cancer	2.61e-05	9.42e-05	CcSEcCtD
Mefenamic acid—Dyspepsia—Prednisone—hematologic cancer	2.59e-05	9.36e-05	CcSEcCtD
Mefenamic acid—Rash—Etoposide—hematologic cancer	2.59e-05	9.35e-05	CcSEcCtD
Mefenamic acid—Dermatitis—Etoposide—hematologic cancer	2.59e-05	9.35e-05	CcSEcCtD
Mefenamic acid—Headache—Etoposide—hematologic cancer	2.57e-05	9.29e-05	CcSEcCtD
Mefenamic acid—Flatulence—Doxorubicin—hematologic cancer	2.57e-05	9.29e-05	CcSEcCtD
Mefenamic acid—Tension—Doxorubicin—hematologic cancer	2.56e-05	9.25e-05	CcSEcCtD
Mefenamic acid—Decreased appetite—Prednisone—hematologic cancer	2.56e-05	9.24e-05	CcSEcCtD
Mefenamic acid—Rash—Prednisolone—hematologic cancer	2.55e-05	9.23e-05	CcSEcCtD
Mefenamic acid—Dermatitis—Prednisolone—hematologic cancer	2.55e-05	9.22e-05	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.55e-05	9.21e-05	CcSEcCtD
Mefenamic acid—Malaise—Epirubicin—hematologic cancer	2.54e-05	9.19e-05	CcSEcCtD
Mefenamic acid—Headache—Prednisolone—hematologic cancer	2.54e-05	9.17e-05	CcSEcCtD
Mefenamic acid—Discomfort—Methotrexate—hematologic cancer	2.53e-05	9.16e-05	CcSEcCtD
Mefenamic acid—Nervousness—Doxorubicin—hematologic cancer	2.53e-05	9.16e-05	CcSEcCtD
Mefenamic acid—Vertigo—Epirubicin—hematologic cancer	2.53e-05	9.15e-05	CcSEcCtD
Mefenamic acid—Syncope—Epirubicin—hematologic cancer	2.53e-05	9.14e-05	CcSEcCtD
Mefenamic acid—Leukopenia—Epirubicin—hematologic cancer	2.52e-05	9.12e-05	CcSEcCtD
Mefenamic acid—Constipation—Prednisone—hematologic cancer	2.52e-05	9.09e-05	CcSEcCtD
Mefenamic acid—Palpitations—Epirubicin—hematologic cancer	2.49e-05	9e-05	CcSEcCtD
Mefenamic acid—Confusional state—Methotrexate—hematologic cancer	2.48e-05	8.96e-05	CcSEcCtD
Mefenamic acid—Loss of consciousness—Epirubicin—hematologic cancer	2.48e-05	8.96e-05	CcSEcCtD
Mefenamic acid—Dizziness—Triamcinolone—hematologic cancer	2.46e-05	8.9e-05	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Methotrexate—hematologic cancer	2.46e-05	8.89e-05	CcSEcCtD
Mefenamic acid—Vision blurred—Doxorubicin—hematologic cancer	2.46e-05	8.89e-05	CcSEcCtD
Mefenamic acid—Convulsion—Epirubicin—hematologic cancer	2.44e-05	8.83e-05	CcSEcCtD
Mefenamic acid—Infection—Methotrexate—hematologic cancer	2.44e-05	8.83e-05	CcSEcCtD
Mefenamic acid—Nausea—Etoposide—hematologic cancer	2.44e-05	8.81e-05	CcSEcCtD
Mefenamic acid—Hypertension—Epirubicin—hematologic cancer	2.43e-05	8.8e-05	CcSEcCtD
Mefenamic acid—Feeling abnormal—Prednisone—hematologic cancer	2.42e-05	8.76e-05	CcSEcCtD
Mefenamic acid—Asthenia—Dexamethasone—hematologic cancer	2.42e-05	8.76e-05	CcSEcCtD
Mefenamic acid—Asthenia—Betamethasone—hematologic cancer	2.42e-05	8.76e-05	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Doxorubicin—hematologic cancer	2.42e-05	8.75e-05	CcSEcCtD
Mefenamic acid—Anaemia—Doxorubicin—hematologic cancer	2.41e-05	8.71e-05	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Methotrexate—hematologic cancer	2.41e-05	8.7e-05	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Prednisone—hematologic cancer	2.41e-05	8.69e-05	CcSEcCtD
Mefenamic acid—Nausea—Prednisolone—hematologic cancer	2.41e-05	8.69e-05	CcSEcCtD
Mefenamic acid—Anxiety—Epirubicin—hematologic cancer	2.39e-05	8.65e-05	CcSEcCtD
Mefenamic acid—Pruritus—Dexamethasone—hematologic cancer	2.39e-05	8.64e-05	CcSEcCtD
Mefenamic acid—Pruritus—Betamethasone—hematologic cancer	2.39e-05	8.64e-05	CcSEcCtD
Mefenamic acid—Skin disorder—Methotrexate—hematologic cancer	2.39e-05	8.63e-05	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.38e-05	8.62e-05	CcSEcCtD
Mefenamic acid—Discomfort—Epirubicin—hematologic cancer	2.37e-05	8.57e-05	CcSEcCtD
Mefenamic acid—Vomiting—Triamcinolone—hematologic cancer	2.37e-05	8.56e-05	CcSEcCtD
Mefenamic acid—Malaise—Doxorubicin—hematologic cancer	2.35e-05	8.5e-05	CcSEcCtD
Mefenamic acid—Rash—Triamcinolone—hematologic cancer	2.35e-05	8.48e-05	CcSEcCtD
Mefenamic acid—Dry mouth—Epirubicin—hematologic cancer	2.35e-05	8.48e-05	CcSEcCtD
Mefenamic acid—Dermatitis—Triamcinolone—hematologic cancer	2.35e-05	8.48e-05	CcSEcCtD
Mefenamic acid—Vertigo—Doxorubicin—hematologic cancer	2.34e-05	8.47e-05	CcSEcCtD
Mefenamic acid—Anorexia—Methotrexate—hematologic cancer	2.34e-05	8.47e-05	CcSEcCtD
Mefenamic acid—Syncope—Doxorubicin—hematologic cancer	2.34e-05	8.46e-05	CcSEcCtD
Mefenamic acid—Urticaria—Prednisone—hematologic cancer	2.34e-05	8.45e-05	CcSEcCtD
Mefenamic acid—Leukopenia—Doxorubicin—hematologic cancer	2.34e-05	8.44e-05	CcSEcCtD
Mefenamic acid—Headache—Triamcinolone—hematologic cancer	2.33e-05	8.43e-05	CcSEcCtD
Mefenamic acid—Abdominal pain—Prednisone—hematologic cancer	2.33e-05	8.41e-05	CcSEcCtD
Mefenamic acid—Body temperature increased—Prednisone—hematologic cancer	2.33e-05	8.41e-05	CcSEcCtD
Mefenamic acid—Confusional state—Epirubicin—hematologic cancer	2.32e-05	8.39e-05	CcSEcCtD
Mefenamic acid—Diarrhoea—Dexamethasone—hematologic cancer	2.31e-05	8.35e-05	CcSEcCtD
Mefenamic acid—Diarrhoea—Betamethasone—hematologic cancer	2.31e-05	8.35e-05	CcSEcCtD
Mefenamic acid—Palpitations—Doxorubicin—hematologic cancer	2.31e-05	8.33e-05	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Epirubicin—hematologic cancer	2.3e-05	8.32e-05	CcSEcCtD
Mefenamic acid—Oedema—Epirubicin—hematologic cancer	2.3e-05	8.32e-05	CcSEcCtD
Mefenamic acid—Hypotension—Methotrexate—hematologic cancer	2.3e-05	8.3e-05	CcSEcCtD
Mefenamic acid—Loss of consciousness—Doxorubicin—hematologic cancer	2.29e-05	8.29e-05	CcSEcCtD
Mefenamic acid—Infection—Epirubicin—hematologic cancer	2.29e-05	8.26e-05	CcSEcCtD
Mefenamic acid—Shock—Epirubicin—hematologic cancer	2.26e-05	8.18e-05	CcSEcCtD
Mefenamic acid—Convulsion—Doxorubicin—hematologic cancer	2.26e-05	8.17e-05	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Epirubicin—hematologic cancer	2.25e-05	8.14e-05	CcSEcCtD
Mefenamic acid—Hypertension—Doxorubicin—hematologic cancer	2.25e-05	8.14e-05	CcSEcCtD
Mefenamic acid—Tachycardia—Epirubicin—hematologic cancer	2.25e-05	8.12e-05	CcSEcCtD
Mefenamic acid—Skin disorder—Epirubicin—hematologic cancer	2.24e-05	8.08e-05	CcSEcCtD
Mefenamic acid—Dizziness—Betamethasone—hematologic cancer	2.23e-05	8.07e-05	CcSEcCtD
Mefenamic acid—Dizziness—Dexamethasone—hematologic cancer	2.23e-05	8.07e-05	CcSEcCtD
Mefenamic acid—Insomnia—Methotrexate—hematologic cancer	2.22e-05	8.04e-05	CcSEcCtD
Mefenamic acid—Anxiety—Doxorubicin—hematologic cancer	2.21e-05	8e-05	CcSEcCtD
Mefenamic acid—Nausea—Triamcinolone—hematologic cancer	2.21e-05	7.99e-05	CcSEcCtD
Mefenamic acid—Paraesthesia—Methotrexate—hematologic cancer	2.21e-05	7.98e-05	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.21e-05	7.97e-05	CcSEcCtD
Mefenamic acid—Discomfort—Doxorubicin—hematologic cancer	2.19e-05	7.93e-05	CcSEcCtD
Mefenamic acid—Anorexia—Epirubicin—hematologic cancer	2.19e-05	7.93e-05	CcSEcCtD
Mefenamic acid—Dyspnoea—Methotrexate—hematologic cancer	2.19e-05	7.92e-05	CcSEcCtD
Mefenamic acid—Somnolence—Methotrexate—hematologic cancer	2.19e-05	7.9e-05	CcSEcCtD
Mefenamic acid—Dry mouth—Doxorubicin—hematologic cancer	2.17e-05	7.85e-05	CcSEcCtD
Mefenamic acid—Dyspepsia—Methotrexate—hematologic cancer	2.16e-05	7.82e-05	CcSEcCtD
Mefenamic acid—Hypotension—Epirubicin—hematologic cancer	2.15e-05	7.77e-05	CcSEcCtD
Mefenamic acid—Vomiting—Dexamethasone—hematologic cancer	2.15e-05	7.76e-05	CcSEcCtD
Mefenamic acid—Vomiting—Betamethasone—hematologic cancer	2.15e-05	7.76e-05	CcSEcCtD
Mefenamic acid—Confusional state—Doxorubicin—hematologic cancer	2.15e-05	7.76e-05	CcSEcCtD
Mefenamic acid—Decreased appetite—Methotrexate—hematologic cancer	2.14e-05	7.72e-05	CcSEcCtD
Mefenamic acid—Rash—Dexamethasone—hematologic cancer	2.13e-05	7.7e-05	CcSEcCtD
Mefenamic acid—Rash—Betamethasone—hematologic cancer	2.13e-05	7.7e-05	CcSEcCtD
Mefenamic acid—Oedema—Doxorubicin—hematologic cancer	2.13e-05	7.69e-05	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Doxorubicin—hematologic cancer	2.13e-05	7.69e-05	CcSEcCtD
Mefenamic acid—Dermatitis—Betamethasone—hematologic cancer	2.13e-05	7.69e-05	CcSEcCtD
Mefenamic acid—Dermatitis—Dexamethasone—hematologic cancer	2.13e-05	7.69e-05	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.12e-05	7.67e-05	CcSEcCtD
Mefenamic acid—Headache—Dexamethasone—hematologic cancer	2.12e-05	7.65e-05	CcSEcCtD
Mefenamic acid—Headache—Betamethasone—hematologic cancer	2.12e-05	7.65e-05	CcSEcCtD
Mefenamic acid—Infection—Doxorubicin—hematologic cancer	2.12e-05	7.64e-05	CcSEcCtD
Mefenamic acid—Asthenia—Prednisone—hematologic cancer	2.11e-05	7.63e-05	CcSEcCtD
Mefenamic acid—Shock—Doxorubicin—hematologic cancer	2.09e-05	7.57e-05	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Doxorubicin—hematologic cancer	2.08e-05	7.53e-05	CcSEcCtD
Mefenamic acid—Pruritus—Prednisone—hematologic cancer	2.08e-05	7.52e-05	CcSEcCtD
Mefenamic acid—Insomnia—Epirubicin—hematologic cancer	2.08e-05	7.52e-05	CcSEcCtD
Mefenamic acid—Tachycardia—Doxorubicin—hematologic cancer	2.08e-05	7.51e-05	CcSEcCtD
Mefenamic acid—Skin disorder—Doxorubicin—hematologic cancer	2.07e-05	7.47e-05	CcSEcCtD
Mefenamic acid—Paraesthesia—Epirubicin—hematologic cancer	2.07e-05	7.47e-05	CcSEcCtD
Mefenamic acid—Dyspnoea—Epirubicin—hematologic cancer	2.05e-05	7.41e-05	CcSEcCtD
Mefenamic acid—Somnolence—Epirubicin—hematologic cancer	2.05e-05	7.39e-05	CcSEcCtD
Mefenamic acid—Anorexia—Doxorubicin—hematologic cancer	2.03e-05	7.33e-05	CcSEcCtD
Mefenamic acid—Feeling abnormal—Methotrexate—hematologic cancer	2.03e-05	7.32e-05	CcSEcCtD
Mefenamic acid—Dyspepsia—Epirubicin—hematologic cancer	2.03e-05	7.32e-05	CcSEcCtD
Mefenamic acid—Diarrhoea—Prednisone—hematologic cancer	2.01e-05	7.28e-05	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Methotrexate—hematologic cancer	2.01e-05	7.27e-05	CcSEcCtD
Mefenamic acid—Nausea—Betamethasone—hematologic cancer	2.01e-05	7.25e-05	CcSEcCtD
Mefenamic acid—Nausea—Dexamethasone—hematologic cancer	2.01e-05	7.25e-05	CcSEcCtD
Mefenamic acid—Decreased appetite—Epirubicin—hematologic cancer	2e-05	7.23e-05	CcSEcCtD
Mefenamic acid—Hypotension—Doxorubicin—hematologic cancer	1.99e-05	7.19e-05	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.99e-05	7.18e-05	CcSEcCtD
Mefenamic acid—Constipation—Epirubicin—hematologic cancer	1.97e-05	7.11e-05	CcSEcCtD
Mefenamic acid—Urticaria—Methotrexate—hematologic cancer	1.95e-05	7.06e-05	CcSEcCtD
Mefenamic acid—Dizziness—Prednisone—hematologic cancer	1.95e-05	7.03e-05	CcSEcCtD
Mefenamic acid—Abdominal pain—Methotrexate—hematologic cancer	1.94e-05	7.02e-05	CcSEcCtD
Mefenamic acid—Body temperature increased—Methotrexate—hematologic cancer	1.94e-05	7.02e-05	CcSEcCtD
Mefenamic acid—Insomnia—Doxorubicin—hematologic cancer	1.93e-05	6.96e-05	CcSEcCtD
Mefenamic acid—Paraesthesia—Doxorubicin—hematologic cancer	1.91e-05	6.91e-05	CcSEcCtD
Mefenamic acid—Dyspnoea—Doxorubicin—hematologic cancer	1.9e-05	6.86e-05	CcSEcCtD
Mefenamic acid—Feeling abnormal—Epirubicin—hematologic cancer	1.9e-05	6.85e-05	CcSEcCtD
Mefenamic acid—Somnolence—Doxorubicin—hematologic cancer	1.89e-05	6.84e-05	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Epirubicin—hematologic cancer	1.88e-05	6.8e-05	CcSEcCtD
Mefenamic acid—Dyspepsia—Doxorubicin—hematologic cancer	1.87e-05	6.77e-05	CcSEcCtD
Mefenamic acid—Vomiting—Prednisone—hematologic cancer	1.87e-05	6.76e-05	CcSEcCtD
Mefenamic acid—Rash—Prednisone—hematologic cancer	1.86e-05	6.7e-05	CcSEcCtD
Mefenamic acid—Dermatitis—Prednisone—hematologic cancer	1.85e-05	6.7e-05	CcSEcCtD
Mefenamic acid—Decreased appetite—Doxorubicin—hematologic cancer	1.85e-05	6.69e-05	CcSEcCtD
Mefenamic acid—Headache—Prednisone—hematologic cancer	1.84e-05	6.66e-05	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.84e-05	6.64e-05	CcSEcCtD
Mefenamic acid—Urticaria—Epirubicin—hematologic cancer	1.83e-05	6.61e-05	CcSEcCtD
Mefenamic acid—Constipation—Doxorubicin—hematologic cancer	1.82e-05	6.58e-05	CcSEcCtD
Mefenamic acid—Abdominal pain—Epirubicin—hematologic cancer	1.82e-05	6.57e-05	CcSEcCtD
Mefenamic acid—Body temperature increased—Epirubicin—hematologic cancer	1.82e-05	6.57e-05	CcSEcCtD
Mefenamic acid—Asthenia—Methotrexate—hematologic cancer	1.76e-05	6.38e-05	CcSEcCtD
Mefenamic acid—Feeling abnormal—Doxorubicin—hematologic cancer	1.75e-05	6.34e-05	CcSEcCtD
Mefenamic acid—Nausea—Prednisone—hematologic cancer	1.75e-05	6.32e-05	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.74e-05	6.29e-05	CcSEcCtD
Mefenamic acid—Pruritus—Methotrexate—hematologic cancer	1.74e-05	6.29e-05	CcSEcCtD
Mefenamic acid—Urticaria—Doxorubicin—hematologic cancer	1.69e-05	6.11e-05	CcSEcCtD
Mefenamic acid—Abdominal pain—Doxorubicin—hematologic cancer	1.68e-05	6.08e-05	CcSEcCtD
Mefenamic acid—Body temperature increased—Doxorubicin—hematologic cancer	1.68e-05	6.08e-05	CcSEcCtD
Mefenamic acid—Diarrhoea—Methotrexate—hematologic cancer	1.68e-05	6.08e-05	CcSEcCtD
Mefenamic acid—Asthenia—Epirubicin—hematologic cancer	1.65e-05	5.97e-05	CcSEcCtD
Mefenamic acid—Pruritus—Epirubicin—hematologic cancer	1.63e-05	5.88e-05	CcSEcCtD
Mefenamic acid—Dizziness—Methotrexate—hematologic cancer	1.63e-05	5.88e-05	CcSEcCtD
Mefenamic acid—Diarrhoea—Epirubicin—hematologic cancer	1.57e-05	5.69e-05	CcSEcCtD
Mefenamic acid—Vomiting—Methotrexate—hematologic cancer	1.56e-05	5.65e-05	CcSEcCtD
Mefenamic acid—Rash—Methotrexate—hematologic cancer	1.55e-05	5.6e-05	CcSEcCtD
Mefenamic acid—Dermatitis—Methotrexate—hematologic cancer	1.55e-05	5.6e-05	CcSEcCtD
Mefenamic acid—Headache—Methotrexate—hematologic cancer	1.54e-05	5.57e-05	CcSEcCtD
Mefenamic acid—Asthenia—Doxorubicin—hematologic cancer	1.53e-05	5.52e-05	CcSEcCtD
Mefenamic acid—Dizziness—Epirubicin—hematologic cancer	1.52e-05	5.5e-05	CcSEcCtD
Mefenamic acid—Pruritus—Doxorubicin—hematologic cancer	1.51e-05	5.44e-05	CcSEcCtD
Mefenamic acid—Vomiting—Epirubicin—hematologic cancer	1.46e-05	5.29e-05	CcSEcCtD
Mefenamic acid—Nausea—Methotrexate—hematologic cancer	1.46e-05	5.28e-05	CcSEcCtD
Mefenamic acid—Diarrhoea—Doxorubicin—hematologic cancer	1.46e-05	5.26e-05	CcSEcCtD
Mefenamic acid—Rash—Epirubicin—hematologic cancer	1.45e-05	5.24e-05	CcSEcCtD
Mefenamic acid—Dermatitis—Epirubicin—hematologic cancer	1.45e-05	5.24e-05	CcSEcCtD
Mefenamic acid—Headache—Epirubicin—hematologic cancer	1.44e-05	5.21e-05	CcSEcCtD
Mefenamic acid—Dizziness—Doxorubicin—hematologic cancer	1.41e-05	5.09e-05	CcSEcCtD
Mefenamic acid—Nausea—Epirubicin—hematologic cancer	1.37e-05	4.94e-05	CcSEcCtD
Mefenamic acid—Vomiting—Doxorubicin—hematologic cancer	1.35e-05	4.89e-05	CcSEcCtD
Mefenamic acid—Rash—Doxorubicin—hematologic cancer	1.34e-05	4.85e-05	CcSEcCtD
Mefenamic acid—Dermatitis—Doxorubicin—hematologic cancer	1.34e-05	4.85e-05	CcSEcCtD
Mefenamic acid—Headache—Doxorubicin—hematologic cancer	1.33e-05	4.82e-05	CcSEcCtD
Mefenamic acid—Nausea—Doxorubicin—hematologic cancer	1.26e-05	4.57e-05	CcSEcCtD
Mefenamic acid—CYP2C8—Metabolism—UGT1A1—hematologic cancer	9.44e-06	9.28e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	9.42e-06	9.26e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—HSP90AA1—hematologic cancer	9.42e-06	9.25e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CBL—hematologic cancer	9.36e-06	9.2e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—SDC1—hematologic cancer	9.35e-06	9.19e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	9.29e-06	9.12e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—STAT3—hematologic cancer	9.26e-06	9.1e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—NRAS—hematologic cancer	9.24e-06	9.08e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—FGF2—hematologic cancer	9.22e-06	9.06e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—MAPK3—hematologic cancer	9.21e-06	9.05e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—SLC22A1—hematologic cancer	9.19e-06	9.02e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CRABP1—hematologic cancer	9.19e-06	9.02e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—PIK3CA—hematologic cancer	9.09e-06	8.93e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PIK3R1—hematologic cancer	9.09e-06	8.93e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	9.07e-06	8.91e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ARNTL—hematologic cancer	9.04e-06	8.88e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—MYC—hematologic cancer	8.96e-06	8.8e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—ALOX5—hematologic cancer	8.95e-06	8.79e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—TGFB1—hematologic cancer	8.94e-06	8.78e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	8.94e-06	8.78e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—HSP90AA1—hematologic cancer	8.93e-06	8.77e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—AKT1—hematologic cancer	8.87e-06	8.71e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—MAPK3—hematologic cancer	8.85e-06	8.69e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—JAK2—hematologic cancer	8.84e-06	8.68e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	8.82e-06	8.67e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ACP5—hematologic cancer	8.79e-06	8.64e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CA9—hematologic cancer	8.79e-06	8.64e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NCOR2—hematologic cancer	8.68e-06	8.52e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PTEN—hematologic cancer	8.67e-06	8.52e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NUP98—hematologic cancer	8.67e-06	8.52e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MDM2—hematologic cancer	8.63e-06	8.47e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—STAT1—hematologic cancer	8.61e-06	8.46e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—MYC—hematologic cancer	8.61e-06	8.46e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—TGFB1—hematologic cancer	8.59e-06	8.44e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	8.48e-06	8.33e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	8.44e-06	8.29e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NCOA3—hematologic cancer	8.42e-06	8.27e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—ADCY7—hematologic cancer	8.42e-06	8.27e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PIK3CB—hematologic cancer	8.39e-06	8.25e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MTOR—hematologic cancer	8.39e-06	8.25e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NUP214—hematologic cancer	8.36e-06	8.21e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—GSTP1—hematologic cancer	8.36e-06	8.21e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—KRAS—hematologic cancer	8.28e-06	8.13e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—EP300—hematologic cancer	8.27e-06	8.13e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	8.27e-06	8.12e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—IDH1—hematologic cancer	8.27e-06	8.12e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—MTR—hematologic cancer	8.19e-06	8.04e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—ABCG2—hematologic cancer	8.19e-06	8.04e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTO1—hematologic cancer	8.17e-06	8.03e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ABCC3—hematologic cancer	8.17e-06	8.03e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—TXN—hematologic cancer	8.17e-06	8.03e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	8.09e-06	7.94e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—GRB2—hematologic cancer	8.06e-06	7.91e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PDGFA—hematologic cancer	8.04e-06	7.89e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—ENO2—hematologic cancer	8.03e-06	7.89e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—SPHK1—hematologic cancer	8e-06	7.86e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—NQO1—hematologic cancer	7.95e-06	7.81e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CD44—hematologic cancer	7.95e-06	7.81e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—KRAS—hematologic cancer	7.95e-06	7.81e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—KITLG—hematologic cancer	7.92e-06	7.78e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—ABCB1—hematologic cancer	7.91e-06	7.77e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CDKN1B—hematologic cancer	7.88e-06	7.74e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	7.79e-06	7.65e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTT1—hematologic cancer	7.79e-06	7.65e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—STAT5A—hematologic cancer	7.74e-06	7.61e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CASP3—hematologic cancer	7.72e-06	7.58e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—IL2—hematologic cancer	7.71e-06	7.57e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—UGT1A1—hematologic cancer	7.69e-06	7.55e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—GSTM1—hematologic cancer	7.68e-06	7.54e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—NCOR1—hematologic cancer	7.68e-06	7.54e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CDKN2B—hematologic cancer	7.67e-06	7.54e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	7.67e-06	7.53e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—SDC1—hematologic cancer	7.61e-06	7.48e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—PIK3CA—hematologic cancer	7.6e-06	7.47e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CYCS—hematologic cancer	7.53e-06	7.39e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CCND1—hematologic cancer	7.51e-06	7.38e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—JUN—hematologic cancer	7.5e-06	7.37e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—HSP90AA1—hematologic cancer	7.48e-06	7.35e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CRABP1—hematologic cancer	7.48e-06	7.34e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—SLC22A1—hematologic cancer	7.48e-06	7.34e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—AKT1—hematologic cancer	7.43e-06	7.3e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CD86—hematologic cancer	7.42e-06	7.29e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—TP53—hematologic cancer	7.36e-06	7.23e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—HES1—hematologic cancer	7.32e-06	7.19e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—PIK3CA—hematologic cancer	7.31e-06	7.18e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ALOX5—hematologic cancer	7.29e-06	7.16e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—NCOR1—hematologic cancer	7.28e-06	7.15e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	7.27e-06	7.14e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CDKN1A—hematologic cancer	7.27e-06	7.14e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PTEN—hematologic cancer	7.25e-06	7.13e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—FGF1—hematologic cancer	7.2e-06	7.07e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	7.18e-06	7.05e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MAPK8—hematologic cancer	7.1e-06	6.97e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—FOXO1—hematologic cancer	7.09e-06	6.97e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PDGFRB—hematologic cancer	7.08e-06	6.96e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NUP98—hematologic cancer	7.06e-06	6.93e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—HRAS—hematologic cancer	7.04e-06	6.91e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PDGFRA—hematologic cancer	6.97e-06	6.85e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—JAK1—hematologic cancer	6.95e-06	6.82e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PRKCG—hematologic cancer	6.95e-06	6.82e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—EP300—hematologic cancer	6.92e-06	6.79e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	6.87e-06	6.74e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ADCY7—hematologic cancer	6.85e-06	6.73e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NCOA3—hematologic cancer	6.85e-06	6.73e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NUP214—hematologic cancer	6.8e-06	6.68e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—MTHFR—hematologic cancer	6.79e-06	6.67e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—HRAS—hematologic cancer	6.76e-06	6.64e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—IL6—hematologic cancer	6.73e-06	6.61e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	6.73e-06	6.61e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	6.73e-06	6.61e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—SRC—hematologic cancer	6.73e-06	6.61e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ABCG2—hematologic cancer	6.66e-06	6.55e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—MTR—hematologic cancer	6.66e-06	6.55e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GSTP1—hematologic cancer	6.63e-06	6.52e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—VEGFA—hematologic cancer	6.55e-06	6.44e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ENO2—hematologic cancer	6.53e-06	6.42e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—STAT3—hematologic cancer	6.49e-06	6.37e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NQO1—hematologic cancer	6.47e-06	6.36e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CD44—hematologic cancer	6.47e-06	6.36e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—NRAS—hematologic cancer	6.47e-06	6.36e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—IL6—hematologic cancer	6.47e-06	6.36e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MTHFR—hematologic cancer	6.43e-06	6.32e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	6.42e-06	6.31e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—TERT—hematologic cancer	6.42e-06	6.3e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—HLA-A—hematologic cancer	6.42e-06	6.3e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTT1—hematologic cancer	6.34e-06	6.23e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	6.34e-06	6.23e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—ABCB1—hematologic cancer	6.28e-06	6.17e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PDGFB—hematologic cancer	6.26e-06	6.15e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	6.24e-06	6.13e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—AKT1—hematologic cancer	6.21e-06	6.1e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MAPK3—hematologic cancer	6.2e-06	6.09e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—SDC1—hematologic cancer	6.19e-06	6.09e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYCS—hematologic cancer	6.12e-06	6.02e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—TSC2—hematologic cancer	6.12e-06	6.01e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PIK3CA—hematologic cancer	6.12e-06	6.01e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—NCOR1—hematologic cancer	6.1e-06	5.99e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GSTM1—hematologic cancer	6.1e-06	5.99e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—HSP90AA1—hematologic cancer	6.09e-06	5.98e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MYC—hematologic cancer	6.03e-06	5.92e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TGFB1—hematologic cancer	6.01e-06	5.91e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.98e-06	5.88e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—AKT1—hematologic cancer	5.97e-06	5.86e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	5.92e-06	5.81e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—FGFR3—hematologic cancer	5.89e-06	5.78e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	5.84e-06	5.74e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PIK3CG—hematologic cancer	5.7e-06	5.6e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	5.59e-06	5.49e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—BAD—hematologic cancer	5.58e-06	5.48e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—KRAS—hematologic cancer	5.57e-06	5.47e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—NOTCH1—hematologic cancer	5.53e-06	5.43e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.48e-06	5.38e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CD80—hematologic cancer	5.42e-06	5.32e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—KIT—hematologic cancer	5.41e-06	5.31e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTP1—hematologic cancer	5.4e-06	5.3e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—MTHFR—hematologic cancer	5.39e-06	5.29e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PTPN11—hematologic cancer	5.31e-06	5.22e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—CREBBP—hematologic cancer	5.29e-06	5.19e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NQO1—hematologic cancer	5.27e-06	5.17e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CD44—hematologic cancer	5.27e-06	5.17e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.22e-06	5.13e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	5.16e-06	5.07e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CREB1—hematologic cancer	5.15e-06	5.05e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PIK3CA—hematologic cancer	5.12e-06	5.03e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—ABCB1—hematologic cancer	5.11e-06	5.02e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—BRAF—hematologic cancer	5.08e-06	4.99e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—IL6R—hematologic cancer	5.02e-06	4.93e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PIK3CD—hematologic cancer	5.01e-06	4.92e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CREBBP—hematologic cancer	5.01e-06	4.92e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—AKT1—hematologic cancer	5e-06	4.91e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYCS—hematologic cancer	4.98e-06	4.9e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NCOR1—hematologic cancer	4.96e-06	4.87e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTM1—hematologic cancer	4.96e-06	4.87e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	4.95e-06	4.86e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TP53—hematologic cancer	4.95e-06	4.86e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—ALB—hematologic cancer	4.95e-06	4.86e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MAP2K1—hematologic cancer	4.78e-06	4.7e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PIK3CD—hematologic cancer	4.75e-06	4.67e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.75e-06	4.66e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—HRAS—hematologic cancer	4.73e-06	4.65e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PIK3R1—hematologic cancer	4.73e-06	4.65e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—FGF2—hematologic cancer	4.55e-06	4.47e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—IL6—hematologic cancer	4.53e-06	4.45e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PIK3CG—hematologic cancer	4.53e-06	4.45e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PIK3R1—hematologic cancer	4.49e-06	4.41e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	4.46e-06	4.38e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTP1—hematologic cancer	4.39e-06	4.32e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—MTHFR—hematologic cancer	4.38e-06	4.31e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PIK3CB—hematologic cancer	4.37e-06	4.29e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—JAK2—hematologic cancer	4.36e-06	4.28e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MDM2—hematologic cancer	4.26e-06	4.18e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.25e-06	4.18e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CREBBP—hematologic cancer	4.2e-06	4.12e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—AKT1—hematologic cancer	4.18e-06	4.11e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ABCB1—hematologic cancer	4.16e-06	4.09e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MTOR—hematologic cancer	4.14e-06	4.07e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PIK3CB—hematologic cancer	4.14e-06	4.07e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CD4—hematologic cancer	4.13e-06	4.06e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTM1—hematologic cancer	4.04e-06	3.97e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NCOR1—hematologic cancer	4.04e-06	3.97e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PIK3CD—hematologic cancer	3.98e-06	3.91e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—ALB—hematologic cancer	3.93e-06	3.86e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CDKN1B—hematologic cancer	3.89e-06	3.82e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.86e-06	3.8e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PTEN—hematologic cancer	3.78e-06	3.71e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PIK3R1—hematologic cancer	3.76e-06	3.69e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PIK3CG—hematologic cancer	3.68e-06	3.62e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—EP300—hematologic cancer	3.6e-06	3.54e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CDKN1A—hematologic cancer	3.59e-06	3.52e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PTEN—hematologic cancer	3.58e-06	3.52e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—MTHFR—hematologic cancer	3.57e-06	3.5e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PIK3CB—hematologic cancer	3.47e-06	3.41e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CREBBP—hematologic cancer	3.42e-06	3.35e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—EP300—hematologic cancer	3.41e-06	3.35e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—SRC—hematologic cancer	3.32e-06	3.26e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PIK3CD—hematologic cancer	3.24e-06	3.18e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—STAT3—hematologic cancer	3.2e-06	3.14e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—ALB—hematologic cancer	3.2e-06	3.14e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—NRAS—hematologic cancer	3.19e-06	3.14e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.14e-06	3.09e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MAPK3—hematologic cancer	3.06e-06	3e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PIK3R1—hematologic cancer	3.06e-06	3e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PIK3CG—hematologic cancer	3e-06	2.94e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PTEN—hematologic cancer	3e-06	2.94e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MYC—hematologic cancer	2.97e-06	2.92e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—TGFB1—hematologic cancer	2.97e-06	2.91e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—EP300—hematologic cancer	2.86e-06	2.81e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PIK3CB—hematologic cancer	2.82e-06	2.77e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CREBBP—hematologic cancer	2.78e-06	2.73e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—KRAS—hematologic cancer	2.75e-06	2.7e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PIK3CA—hematologic cancer	2.66e-06	2.62e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PIK3CD—hematologic cancer	2.64e-06	2.59e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ALB—hematologic cancer	2.6e-06	2.56e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PIK3CA—hematologic cancer	2.52e-06	2.48e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PIK3R1—hematologic cancer	2.49e-06	2.44e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PTEN—hematologic cancer	2.44e-06	2.4e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—HRAS—hematologic cancer	2.34e-06	2.29e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—EP300—hematologic cancer	2.33e-06	2.28e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PIK3CB—hematologic cancer	2.3e-06	2.26e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—IL6—hematologic cancer	2.24e-06	2.2e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—AKT1—hematologic cancer	2.18e-06	2.14e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PIK3CA—hematologic cancer	2.11e-06	2.08e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—AKT1—hematologic cancer	2.06e-06	2.03e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PTEN—hematologic cancer	1.98e-06	1.95e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—EP300—hematologic cancer	1.89e-06	1.86e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—AKT1—hematologic cancer	1.73e-06	1.7e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PIK3CA—hematologic cancer	1.72e-06	1.69e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—AKT1—hematologic cancer	1.41e-06	1.38e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PIK3CA—hematologic cancer	1.4e-06	1.38e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—AKT1—hematologic cancer	1.14e-06	1.12e-05	CbGpPWpGaD
